Immune-directed therapy for type 1 diabetes at the clinical level: The Immune Tolerance Network (ITN) experience

Review of Diabetic Studies

Volumn 9, Issue 4, 2012, Pages 359-371

  Ehlers, Mario R ^a   Nepom, Gerald T ^b  

^a Immune Tolerance Network   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

AbATE; Adaptive trials; Alefacept; Alpha 1 antitrypsin; Anti CD3; Antithymocyte globulin; Autoimmunity; Beta cell; Combination therapy; IL 2 rapa; Immune tolerance; New onset type 1 diabetes; RETAIN; START; T1DAL

Indexed keywords

ALEFACEPT; ALPHA 1 ANTITRYPSIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN A1C; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; THYMOCYTE ANTIBODY;

ANTIGEN SPECIFICITY; APOPTOSIS; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; EMPHYSEMA; EOSINOPHILIA; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFLAMMATION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MELANOMA; POLYMERASE CHAIN REACTION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 84879517841     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2012.9.359     Document Type: Review

References (53)

1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010. 464:1293-1300.
2. Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes. Nat Rev Drug Disc 2011. 10:439-452.
3. Skyler JS, Ricordi C. Stopping type 1 diabetes: Attempts to prevent or cure type 1 diabetes in man. Diabetes 2011. 60:1-8.
4. Mandrup-Poulsen T. Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes. Rev Diabet Stud 2012. 9(4):338-347.
5. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003. 26:832-836.
6. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function. Diabetes 2004. 53:250-264.
7. Lachin JM, McGee PL, Greenbaum CJ, Palmer J, Pescovitz MD, Gottlieb P, Skyler J, Type 1 Diabetes Trial Network. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type diabetes. Plos One 2011. 6:e26471.
8. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, Type 1 Diabetes TrialNet Research Group, European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008. 31:1966-1971.
9. Chatenoud L, Bluestone JA. CD3-specific antibodies: A portal to the treatment of autoimmunity. Nat Rev Immunol 2007. 7:622-632.
10. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluetsone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002. 346:1692-1698.
11. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005. 352:2598-2608.
12. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomized controlled trial. Diabetologia 2012. In press.
13. Herold KC, Ehlers M, Boyle K, McNamara J, Gitelman S, Gottlieb P, Greenbaum C, Hagopian W, Bluestone JA. Metabolic parameters at baseline identify clinical responders to teplizumab 2 years after diagnosis of type 1 diabetes. Diabetologia 2012. 55(Suppl 1):S191.
14. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCVinduced vasculitis. N Engl J Med 2011. 365:2067-2077.
15. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011. 365:2055-2066.
16. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggaewal S, Phippard D, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012. 61:2340-2348.
17. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, Bromberg JS, Dong HH. Sirolimus is associated with reduced islet engraftment and impaired betacell function. Diabetes 2006. 55:2429-2436.
18. Valle A, Jofra T, Stabilini A, Atkinson M, Roncarolo MG, Battaglia M. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 2009. 58:875-881.
19. Piemonti L, Maffi P, Monti L, Lampasona V, Perseghin G, Magistretti P, Secchi A, Bonifacio E. Beta cell function during rapamycin monotherapy in longterm type 1 diabetes. Diabetologia 2011. 54:433-439.
20. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, Morris MA. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985. 2:271-276.
21. Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004. 1:80-88.
22. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007. 297:1568-1576.
23. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009. 301:1573-1579.
24. Gitelman SE, Fisher LK, Gottlieb PA, Gottschalk M, Moore WV, Moran A, Rigby MR, Willi SM, Keyes-Elstein L, Pinckney A, et al. Effect of anti-thymocyte globulin (ATG) on preserving beta cell function in newonset type 1 diabetes. Diabetologia 2012. 55(Suppl 1):S191.
25. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, et al. Fall in C-peptide during first 2 years from diagnosis. Evidence of at least two distinct phases from composite TrialNet data. Diabetes 2012. 61:2066-2073.
26. Crystal RG. Alpha1-Antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990. 85:1343-1352.
27. Tuder RM, Janciauskiene SM, Petrache I. Lung disease associated with a1-antitrypsin deficiency. Proc Am ThoracSoc 2010. 7:381-386.
28. Janciauskiene SM, Nita IM, Stevens T. Alpha1-Antitrypsin, old dog, new tricks. Alpha1-Antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007. 282:8573-8582.
29. Zhang B, Lu Y, Campbell-Thompson M, Spencer T, Wasserfall C, Atkinson M, Song S. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes 2007. 56:1316-1323.
30. Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. Alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets 2010. 2:185-189.
31. Nita I, Hollander C, Westin U, Janciauskiene SM. Prolastin, a pharmaceutical preparation of purified alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Resp Res 2005. 6:12.
32. Lewis EC, Mizrahi M, Toledano M, DeFelice N, Wright JL, Churg A, Shapiro L, Dinarello CA. Alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA 2008. 105:16236-16241.
33. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA 2008. 105:16242-16247.
34. Ehlers MR, Gottlieb PA, Herold K, Rigby MR, Willi SM, Aggarwal S, Phippard D, Gelmont DM, Jepson B, McNamara J, et al. Alpha-1 antitrypsin therapy in new-onset type 1 diabetes: Interim results from Part I of the RETAIN study. Diabetologia 2012. 55(Suppl 1):S67.
35. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003. 49:S87-S97.
36. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, et al. Rituximab, Blymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009. 361:2143-2152.
37. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomized, double-blind, placebo-controlled trial. Lancet 2011. 378:412-419.
38. Moran A. Canakinumab, an anti-IL-1 monoclonal antibody in recent-onset type 1 diabetes. 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, June 11, 2012.
39. Mandrup-Poulsen T. IL-1 receptor antagonist in recent onset type 1 diabetes: A multicenter randomized, placebocontrolled trial. 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, June 11, 2012.
40. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomized doubleblind trial. Lancet 2011. 378:319-327.
41. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomized, placebo-controlled trial. Lancet 2011. 378:487-497.
42. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010. 160:176-184.
43. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T, Herold KC. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade. Diabetes 2012. 61:145-154.
44. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006. 116:1371-1381.
45. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009. 58:2277-2284.
46. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, et al. Failure to preserve beta-cell function with mycophenolatemofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010. 33:826-832.
47. Sarikonda G, Sachithanantham S, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni P, Schneider D, Calvo TR, et al. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: Immunologic effects and efficacy in NOD mice. Plos One 2013. In press.
48. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: Role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008. 223:371-390.
49. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009. 58:652-662.
50. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, Wujtewicz MA, Witkowski P, Mlynarski W, Balcerska A, et al. Administration of CD4+CD25highCD127-regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012. 35:1817-1820.
51. Horwitz DA, Zheng SG, Wang J, Gray JD. The real role of TGF-beta in regulatory T cells physiology. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp-3+CD4+ Treg. Eur J Immunol 2008. 38:912-915.
52. FDA Guidance for Industry. Adaptive design clinical trials for drugs and biologics. U.S. Food and Drug Administration. February 2010.
53. Jones D. Adaptive trials receive boost. Nat Rev Drug Disc 2010. 9:345-348.